Gael Tisack

I'll research this attorney before drafting.

Let me verify the tracked case and check for PTAB/IPR involvement.

Let me check the specific docket appearances and PTAB matters.

Specialty / focus. Gael Tisack's practice centers on medical devices and diagnostics, with continuous glucose monitoring (CGM) as the dominant technology in her tracked litigation. The single indexed case, Abbott Diabetes Care Inc. v. DexCom, Inc., sits in the CGM/analyte-sensor space, and her public bios and EPO engagement materials confirm Abbott's device portfolio (diabetes care, cardiovascular, neuromodulation) as her primary focus. Her earlier in-house work at Terumo Cardiovascular Systems (blood-handling and transradial-access devices) and Olympus (endoscopy/colonoscopy-assist devices) was likewise life-sciences hardware; her B.S./M.S. in mechanical engineering and prior engineering career at Ford are consistent with the electro-mechanical character of that work. World IP Review lists her practice type as "non-contentious," reflecting a portfolio-strategy emphasis, although her public record shows substantial litigation oversight.

Side preference. She is not a firm-side litigator with a mix of plaintiff and defense engagements. The tracked data — one appearance, plaintiff side, as in-house counsel for Abbott — reflects her role as a corporate IP chief who directs enforcement for an operating company rather than representing NPEs/PAEs or defending accused infringers as outside counsel. Her public statements across employers are consistently enforcement-oriented: Terumo's 2013 suits against Vascular Solutions/Lepu Medical over the TR Band device and against ThermoGenesis/Celling over cellular-therapy patents, and Olympus/Arc Medical's 2021 action against Cantel/Medivators, which settled in December 2021 with Medivators agreeing to stop selling the accused AmplifEYE product. The 1–0 plaintiff/defendant split should be read as a function of a very small sample, not as a firm-side practice pattern.

Firm context. She has no current firm affiliation — she is Chief IP Counsel, Divisional Vice President & Associate General Counsel at Abbott Laboratories, leading a worldwide IP organization. Prior in-house roles: Global Head of Intellectual Property at Olympus Corporation (from 2018); founder and head of the Technology Transfer Office at Wichita State University; and nearly 13 years at Terumo Cardiovascular Systems, rising from patent attorney to Senior Vice President and General Counsel. Her only law-firm role was as an associate at Brinks, Gilson & Lione (now Crowell & Moring) after law school.

Notable matters, PTAB, and credentials. The Abbott–DexCom dispute is the centerpiece: parallel U.S. and UK CGM proceedings, including the Delaware case in which a jury found DexCom infringed Abbott's '649 patent (Abbott sought roughly $1.38 billion, with damages sent to a retrial), the G7 case (C.A. 23-239, dismissed with prejudice in December 2024), the UK Patents Court's January 2024 judgment on EP627, EP223, EP159/EP539, and the Federal Circuit's decision at 89 F.4th 1370 (Fed. Cir. 2024) addressing the parties' settlement agreement and dispute-resolution clause. The entire global dispute settled on December 23, 2024, with all cases in courts and patent offices dismissed and a 10-year mutual covenant not to litigate patent, trade dress, and design rights, with no financial payments disclosed. On the PTAB side, Abbott filed IPR petitions against DexCom patents during this campaign (e.g., IPR2024-00861 on U.S. Patent No. 9,801,541); those filings are consistent with the portfolio she oversees, but I could not verify that she personally appears in PTAB proceedings, so IPR appearance history should not be attributed to her individually. Bar/education: J.D., cum laude, University of Michigan Law School; B.S. and M.S., mechanical engineering, University of Michigan; registered patent attorney before the USPTO and admitted in Michigan (2000). Conference bios are the source for the education and admission details, which I was not able to corroborate against a state bar or firm record.